Perrigo PE Ratio 2010-2024 | PRGO
Current and historical p/e ratio for Perrigo (PRGO) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perrigo PE ratio as of December 20, 2024 is 10.33.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Perrigo PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-12-20 | 25.75 | 0.00 | |
| 2024-09-30 | 25.98 | $-1.17 | 0.00 |
| 2024-06-30 | 25.20 | $-0.92 | 0.00 |
| 2024-03-31 | 31.58 | $-0.07 | 0.00 |
| 2023-12-31 | 31.28 | $-0.10 | 0.00 |
| 2023-09-30 | 30.78 | $0.05 | 615.64 |
| 2023-06-30 | 32.46 | $-0.42 | 0.00 |
| 2023-03-31 | 34.00 | $-0.96 | 0.00 |
| 2022-12-31 | 32.07 | $-0.96 | 0.00 |
| 2022-09-30 | 33.28 | $-0.63 | 0.00 |
| 2022-06-30 | 37.60 | $-0.70 | 0.00 |
| 2022-03-31 | 35.38 | $-0.65 | 0.00 |
| 2021-12-31 | 35.56 | $-1.92 | 0.00 |
| 2021-09-30 | 42.97 | $-3.29 | 0.00 |
| 2021-06-30 | 41.39 | $-2.41 | 0.00 |
| 2020-12-31 | 39.94 | $-1.21 | 0.00 |
| 2020-09-30 | 40.81 | $-0.06 | 0.00 |
| 2020-06-30 | 48.92 | $1.35 | 36.23 |
| 2020-03-31 | 42.39 | $1.58 | 26.83 |
| 2019-12-31 | 45.34 | $0.88 | 51.52 |
| 2021-03-31 | 36.35 | $1.49 | 24.40 |
| 2019-09-30 | 48.85 | $1.81 | 26.99 |
| 2019-06-30 | 41.44 | $0.65 | 63.75 |
| 2019-03-31 | 41.70 | $0.84 | 49.65 |
| 2018-12-31 | 33.42 | $0.94 | 35.56 |
| 2018-09-30 | 61.07 | $0.86 | 71.01 |
| 2018-06-30 | 62.73 | $1.66 | 37.79 |
| 2018-03-31 | 71.52 | $0.91 | 78.59 |
| 2017-12-31 | 74.62 | $0.84 | 88.83 |
| 2017-09-30 | 72.34 | $-9.16 | 0.00 |
| 2017-06-30 | 64.40 | $-18.23 | 0.00 |
| 2017-03-31 | 56.49 | $-16.39 | 0.00 |
| 2016-12-31 | 70.67 | $-19.23 | 0.00 |
| 2016-09-30 | 78.27 | $-10.49 | 0.00 |
| 2016-06-30 | 76.73 | $-0.96 | 0.00 |
| 2016-03-31 | 108.10 | $-2.98 | 0.00 |
| 2015-12-31 | 122.13 | $-0.13 | 0.00 |
| 2015-09-30 | 132.63 | $1.33 | 99.72 |
| 2015-03-31 | 139.43 | $0.56 | 248.98 |
| 2014-12-31 | 140.67 | $1.59 | 88.47 |
| 2014-09-30 | 126.31 | $0.21 | 601.45 |
| 2014-06-30 | 122.49 | $0.67 | 182.83 |
| 2014-03-31 | 129.87 | $0.67 | 193.84 |
| 2013-12-31 | 128.78 | $1.49 | 86.43 |
| 2013-09-30 | 103.48 | $3.48 | 29.74 |
| 2013-06-30 | 101.41 | $3.42 | 29.65 |
| 2013-03-31 | 99.44 | $3.42 | 29.07 |
| 2012-12-31 | 87.05 | $3.47 | 25.09 |
| 2012-09-30 | 97.12 | $3.41 | 28.48 |
| 2012-06-30 | 98.52 | $3.04 | 32.41 |
| 2012-03-31 | 86.24 | $3.04 | 28.37 |
| 2011-12-31 | 81.16 | $2.76 | 29.41 |
| 2011-09-30 | 80.93 | $2.67 | 30.31 |
| 2011-06-30 | 73.18 | $2.72 | 26.90 |
| 2011-03-31 | 66.17 | $2.72 | 24.33 |
| 2010-12-31 | 52.64 | $2.43 | 21.66 |
| 2010-09-30 | 53.32 | $2.01 | 26.53 |
| 2010-06-30 | 49.00 | $1.87 | 26.20 |
| 2010-03-31 | 48.65 | $1.87 | 26.02 |
| 2009-12-31 | 32.96 | $1.70 | 19.39 |
| 2009-09-30 | 28.08 | $1.53 | 18.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.510B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.987B | 24.87 |
| Stryker (SYK) | United States | $136.147B | 30.68 |
| Boston Scientific (BSX) | United States | $130.670B | 37.57 |
| EssilorLuxottica (ESLOY) | France | $110.026B | 0.00 |
| Medtronic (MDT) | Ireland | $102.570B | 15.24 |
| Haleon (HLN) | United Kingdom | $43.909B | 28.53 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.293B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $35.376B | 18.35 |
| ResMed (RMD) | United States | $33.995B | 27.93 |
| Terumo (TRUMY) | Japan | $28.800B | 40.67 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 18.01 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.064B | 13.41 |
| Insulet (PODD) | United States | $17.996B | 71.67 |
| Baxter (BAX) | United States | $14.756B | 9.60 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.838B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.021B | 40.32 |
| Bio-Rad Laboratories (BIO) | United States | $9.125B | 31.01 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.392B | 14.85 |
| Prestige Consumer Healthcare (PBH) | United States | $3.886B | 19.33 |
| Haemonetics (HAE) | United States | $3.862B | 18.85 |
| ICU Medical (ICUI) | United States | $3.751B | 35.71 |
| Envista Holdings (NVST) | United States | $3.103B | 23.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.894B | 18.63 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.605B | 30.05 |
| LeMaitre Vascular (LMAT) | United States | $2.074B | 50.41 |
| Green Thumb Industries (GTBIF) | United States | $1.630B | 28.52 |
| AtriCure (ATRC) | United States | $1.465B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 8.68 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.371B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.304B | 9.32 |
| BioLife Solutions (BLFS) | United States | $1.211B | 0.00 |
| Owens & Minor (OMI) | United States | $0.973B | 7.60 |
| CeriBell (CBLL) | United States | $0.958B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.955B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.883B | 15.58 |
| Evolus (EOLS) | United States | $0.688B | 0.00 |
| Omeros (OMER) | United States | $0.593B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.593B | 26.15 |
| Capricor Therapeutics (CAPR) | United States | $0.587B | 0.00 |
| Surmodics (SRDX) | United States | $0.572B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.445B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.429B | 0.00 |
| Quanterix (QTRX) | United States | $0.383B | 0.00 |
| ZimVie (ZIMV) | United States | $0.373B | 31.44 |
| Valneva SE (VALN) | France | $0.353B | 0.00 |
| Biote (BTMD) | United States | $0.313B | 6.86 |
| Viemed Healthcare (VMD) | United States | $0.312B | 29.70 |
| Canopy Growth (CGC) | Canada | $0.295B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.283B | 18.95 |
| Sanara MedTech (SMTI) | United States | $0.276B | 0.00 |
| Zynex (ZYXI) | United States | $0.268B | 56.00 |
| High Tide (HITI) | Canada | $0.237B | 98.00 |
| Aurora Cannabis (ACB) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.54 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Organigram Holdings (OGI) | Canada | $0.184B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.181B | 0.00 |
| Brainsway (BWAY) | Israel | $0.169B | 89.60 |
| FitLife Brands (FTLF) | United States | $0.151B | 19.04 |
| Jin Medical (ZJYL) | China | $0.132B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.110B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Exagen (XGN) | United States | $0.083B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.066B | 34.17 |
| InterCure (INCR) | Israel | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.042B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.82 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |